AI-Powered skin patch could bring TB prevention to People's doorsteps

NCT ID NCT07714707

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study explores whether community health workers can use a new skin test, with or without AI help, to test close contacts of TB patients at home instead of at a clinic. The goal is to make it easier for people, especially children and families in Tajikistan and Tanzania, to get tested and start preventive treatment. Researchers will compare home-based testing to clinic-based testing to see which approach leads to more people completing their full course of TB prevention.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CY-TB Patch (a skin test patch) and TB Connect app (AI-assisted reading tool)
What this could lead to
If successful, this approach could make TB preventive care more accessible and increase treatment completion rates, reducing TB spread in high-burden communities.
What could go wrong
This is an implementation study, not a drug trial, so it tests logistics and feasibility rather than a new cure. Results may vary between countries and settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TPT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • KNCV Tajikistan

    Dushanbe, Tajikistan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • KNCV Tanzania

    Dar es Salaam, Dar es Salaam Region, Tanzania

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.